Table 3.
Univariate Cox regression analysis for identifying predictors of clinically significant progression
| Predictors | Univariate analysis |
|
|---|---|---|
| HR (95% CI) | p value | |
| Age at diagnosis (yr) | 1.04 (0.99–1.08) | 0.063 |
| Baseline PSA density (ng/ml/ml) | 3.40 (0.63–18.37) | 0.155 |
| Baseline GG | ||
| GG 1 | Reference | – |
| GG 2 | 0.76 (0.24–2.45) | 0.648 |
| Baseline PI-RADS | ||
| PI-RADS 1–2 | Reference | – |
| PI-RADS 3–5 | 1.86 (1.03–3.36) | 0.041 |
| Highest PRECISEa | ||
| PRECISE 1–3 | Reference | – |
| PRECISE 4–5 | 5.09 (2.61–9.95) | <0.001 |
| No. of repeat MRI scans | ||
| 1 | Reference | – |
| 2 | 0.53 (0.28–1.01) | 0.054 |
| ≥3 | 0.181 (0.08–0.43) | <0.001 |
| No. of repeat biopsies | ||
| 0 | Reference | – |
| 1 | 12.48 (3.84–40.49) | <0.001 |
| ≥2 | 7.98 (2.11–30.11) | 0.002 |
CI = confidence interval; GG = Gleason grade group; HR = hazard ratio; MRI = magnetic resonance imaging; PI-RADS = Prostate Imaging Reporting and Data System; PRECISE = Prostate Cancer Radiological Estimation of Change in Sequential Evaluation; PSA = prostate-specific antigen.
a
Highest PRECISE score for each patient.